^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
PD-L1.t-haNK
i
Other names: PD-L1.t-haNK, PD-L1.t-haNK cell therapy, PD-L1 t-haNK
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
ImmunityBio
Drug class:
PD-L1 inhibitor
Related drugs:
6d
QUILT 3.064: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (clinicaltrials.gov)
P1, N=16, Completed, ImmunityBio, Inc. | Active, not recruiting --> Completed
Trial completion
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1.t-haNK
26d
QUILT 3.064: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (clinicaltrials.gov)
P1, N=16, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1.t-haNK
4ms
The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803. (PubMed, Cancer Immunol Immunother)
Enhanced avelumab-mediated antibody-dependent cell-mediated cytotoxicity and lysis by PD-L1 targeting high-affinity NK (PD-L1 t-haNK) cells were observed in tuvusertib-treated DU145. In vivo in the DU145 PCa xenograft model, tuvusertib and N-803 combination therapy demonstrated marked and significant antitumor efficacy relative to either monotherapy, eliciting superior tumor growth control and prolonging survival. Our findings support further investigation into the use of ATRi with immune checkpoint blockade and/or immune-stimulating agents in prostate cancer.
Journal
|
BCL2L1 (BCL2-like 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • IL15 (Interleukin 15) • TNFRSF10B (TNF Receptor Superfamily Member 10b) • NKG2D (killer cell lectin like receptor K1)
|
Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • tuvusertib (M1774) • PD-L1.t-haNK
4ms
QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
P2, N=328, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Oct 2025 --> May 2026
Trial completion date
|
gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • cyclophosphamide • leucovorin calcium • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK • aldoxorubicin (INNO-206)
5ms
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
P2, N=34, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting
Enrollment open
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
6ms
QUILT 3.064: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (clinicaltrials.gov)
P1, N=16, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Dec 2024 --> Nov 2025 | Trial primary completion date: Oct 2024 --> Nov 2025
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
PD-L1.t-haNK
7ms
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
P2, N=34, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting | N=20 --> 34
Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
7ms
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (clinicaltrials.gov)
P2, N=40, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
8ms
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer (clinicaltrials.gov)
P2, N=18, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=55 --> 18
Enrollment closed • Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
HER-2 positive
|
Keytruda (pembrolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
1year
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer (clinicaltrials.gov)
P2, N=55, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
HER-2 positive
|
Keytruda (pembrolizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
1year
Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients. (PubMed, Front Oncol)
From late 2019 to 2021, single-patient Investigational New Drug (spIND) protocols for five mPC patients were designed and approved that generally comprised combined Abraxane (nab-paclitaxel) and gemcitabine therapy with experimental therapeutics N-803, PD-L1-targeted high-affinity natural killer (PD-L1 t-haNK) cells, and aldoxorubicin, a serum albumin-binding doxorubicin prodrug. Some patients also received stereotactic body radiation therapy (SBRT), cyclophosphamide, pembrolizumab, nivolumab, and/or experimental ETBX-051 (brachyury) and/or ETBX-061 (MUC1) vaccines...The OS of 13, 26.9, and 23.2 months for three patients is particularly notable. The findings here support the ongoing clinical investigations of N-803 and PD-L1 t-haNK cells in combination therapy.
Journal
|
PD-L1 (Programmed death ligand 1) • MUC1 (Mucin 1) • CA 19-9 (Cancer antigen 19-9)
|
PD-L1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • gemcitabine • albumin-bound paclitaxel • cyclophosphamide • Anktiva (nogapendekin alfa inbakicept-pmln) • ETBX-051 • ETBX-061 • PD-L1.t-haNK • aldoxorubicin (INNO-206)
over1year
QUILT-3.055: a Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (clinicaltrials.gov)
P2, N=40, Recruiting, ImmunityBio, Inc. | Active, not recruiting --> Recruiting | N=147 --> 40
Enrollment open • Enrollment change • Checkpoint inhibition
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
Share via
